Skip to main content

Idorsia receives payment of 45 million US dollars

| News

Idorsia receives payment of 45 million US dollars

12.05.2020

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy.

Idorsia headquarter in Allschwil (img: Idorsia)

Idorsia has developed a T-type calcium channel blocker in the form of ACT-709478 that should facilitate treatment of a rare form of epilepsy in children. According to a press release, Idorsia has agreed a licensing agreement with Neurocrine Biosciences. As the US company has now decided to take up its option to license the global development and marketing rights to ACT-709478, Idorsia is set to receive fixed payments as part of the agreement.

In this context, the company based in Allschwil receives an upfront payment of 45 million US dollars. Moreover, Idorsia will be entitled to claim milestone payments up to a potential total of 365 million US dollars in addition to tiered royalties dependent on net sales figures. Neurocrine Biosciences is already planning to launch a Phase II study in the second half of 2020.

“If the efficacy of our selective T-type calcium channel blocker seen in preclinical models is confirmed in children with rare pediatric epilepsy, it could transform the life of children with this disease”, comments Martine Clozel, Chief Scientific Officer of Idorsia, in the press release. Furthermore, this is a case where collaborating with a partner allows greater progress to be made in further development processes.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More